Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.90 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.90 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28808948 | 0.96 | PLK1 (0.97) | PLK1PLK3 | |
| SCHEMBL1464569 | 0.84 | PLK1 (0.66) | PLK1PLK3TRPV1SLC16A3 | |
| SCHEMBL16495561 | 0.84 | PLK1 (0.72) | PLK1PLK3TRPV1 | |
| SCHEMBL23657651 | 0.83 | TRPV1 (0.68) | PLK1PLK3TRPV1MEN1NPC1 | |
| SCHEMBL14075407 | 0.83 | PLK1 (0.71) | PLK1PLK3TRPV1 | |
| SCHEMBL2028671 | 0.82 | DHODH (0.86) | PLK1PLK3MEN1NPC1RAB9A | |
| SCHEMBL14075210 | 0.82 | PLK1 (0.69) | PLK1PLK3TRPV1 | |
| SCHEMBL14075264 | 0.82 | PLK1 (0.69) | PLK1PLK3TRPV1MEN1KMT2A | |
| SCHEMBL9337724 | 0.81 | PLK1 (0.62) | PLK1PLK3TRPV1MEN1NPC1 | |
| SCHEMBL5696419 | 0.81 | DHODH (0.69) | PLK1PLK3MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | PLK1 3734/4885PLK3 1566/4885TRPV1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.